Impact of infection or vaccination on pre-existing serological memory

Human Immunology

Volumn 73, Issue 11, 2012, Pages 1082-1086

  Amanna, Ian J ^a,b   Hammarlund, Erika ^a   Lewis, Mathew W ^a   Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Najit Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G; SMALLPOX VACCINE; TETANUS TOXIN; TOLL LIKE RECEPTOR 9; VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; MUMPS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; RUBELLA; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS INFECTION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; YELLOW FEVER FLAVIVIRUS;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFECTION; VACCINATION; VACCINES; VACCINIA; VACCINIA VIRUS;

EID: 84867871333     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.07.328     Document Type: Article

References (22)

1. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903.
2. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125.
3. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199.
4. Radbruch A., Muehlinghaus G., Luger E.O., Inamine A., Smith K.G., Dorner T., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741.
5. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 2007, 8:419.
6. Odendahl M., Mei H., Hoyer B.F., Jacobi A.M., Hansen A., Muehlinghaus G., et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105:1614.
7. Amanna I.J., Slifka M.K. Quantitation of rare memory B cell populations by two independent and complementary approaches. J Immunol Methods 2006, 317:175.
8. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131.
9. Bender R., Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 2001, 54:343.
10. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710.
11. Zhu J., Martinez J., Huang X., Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007, 109:619.
12. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413.
13. West A.P., Koblansky A.A., Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 2006, 22:409.
14. Di Genova G., Roddick J., McNicholl F., Stevenson F.K. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. Blood 2006, 107:2806.
15. Benson M.J., Elgueta R., Schpero W., Molloy M., Zhang W., Usherwood E., et al. Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J Exp Med 2009, 206:2013.
16. Richard K., Pierce S.K., Song W. The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol 2008, 181:1746.
17. Ahuja A., Anderson S.M., Khalil A., Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A 2008, 105:4802.
18. DiLillo D.J., Hamaguchi Y., Ueda Y., Yang K., Uchida J., Haas K.M., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008, 180:361.
19. Cambridge G., Leandro M.J., Edwards J.C., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003, 48:2146.
20. Pescovitz M.D., Torgerson T.R., Ochs H.D., Ocheltree E., McGee P., Krause-Steinrauf H., et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011, 128:1295.
21. Davies D.H., Molina D.M., Wrammert J., Miller J., Hirst S., Mu Y., et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007, 7:1678.
22. Ansong C., Yoon H., Norbeck A.D., Gustin J.K., McDermott J.E., Mottaz H.M., et al. Proteomics analysis of the causative agent of typhoid fever. J Proteome Res 2008, 7:546.